Karuna Therapeutics, Inc. ((KRTX)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Karuna Therapeutics, Inc. is conducting a Phase 3 study titled ‘A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer’s Disease (ADEPT-4).’ The study aims to assess the safety and efficacy of KarXT in adults with mild to severe Alzheimer’s Disease (AD) experiencing moderate to severe psychosis. This research is significant as it addresses a critical need for effective treatments for psychosis in AD patients.
The intervention being tested is KarXT, a drug designed to treat psychosis associated with Alzheimer’s Disease. The study compares the effects of KarXT against a placebo to determine its effectiveness.
The study is interventional, with a randomized and parallel group design. It employs a quadruple masking approach, meaning the participant, care provider, investigator, and outcomes assessor are all blinded to the treatment allocations. The primary purpose of the study is treatment-focused.
The study began on September 26, 2024, with its last update on July 24, 2025. These dates are crucial as they mark the progress and ongoing nature of the research, indicating that the study is currently recruiting participants.
The update on this study could impact Karuna Therapeutics’ stock performance positively if the results show promise, as it would position the company favorably in the market for Alzheimer’s treatments. Investors may view this as a strategic advancement, especially in comparison to competitors in the neuropsychiatric treatment space.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.